Akebia Therapeutics, Inc. (AKBA): Price and Financial Metrics
GET POWR RATINGS... FREE!
AKBA POWR Grades
- AKBA scores best on the Growth dimension, with a Growth rank ahead of 88.57% of US stocks.
- The strongest trend for AKBA is in Growth, which has been heading up over the past 179 days.
- AKBA ranks lowest in Sentiment; there it ranks in the 8th percentile.
AKBA Stock Summary
- Akebia Therapeutics Inc's capital turnover -- a measure of revenue relative to shareholder's equity -- is better than 82.33% of US listed stocks.
- As for revenue growth, note that AKBA's revenue has grown -27.68% over the past 12 months; that beats the revenue growth of only 5.88% of US companies in our set.
- Shareholder yield, a measure of how much is returned to shareholders via dividends and share repurchases, for AKBA comes in at -20.11% -- higher than that of only 18.28% of stocks in our set.
- Stocks that are quantitatively similar to AKBA, based on their financial statements, market capitalization, and price volatility, are CYRN, OPTT, XBIO, AWRE, and CLXT.
- Visit AKBA's SEC page to see the company's official filings. To visit the company's web site, go to www.akebia.com.
AKBA Valuation Summary
- AKBA's price/sales ratio is 2.3; this is 39.47% lower than that of the median Healthcare stock.
- AKBA's price/sales ratio has moved NA NA over the prior 91 months.
- Over the past 91 months, AKBA's price/sales ratio has gone NA NA.
Below are key valuation metrics over time for AKBA.
| Stock | Date | P/S | P/B | P/E | EV/EBIT |
|---|---|---|---|---|---|
| AKBA | 2021-08-31 | 2.3 | 2.9 | -1.7 | -1.3 |
| AKBA | 2021-08-30 | 2.2 | 2.8 | -1.6 | -1.3 |
| AKBA | 2021-08-27 | 2.2 | 2.8 | -1.7 | -1.3 |
| AKBA | 2021-08-26 | 2.1 | 2.6 | -1.5 | -1.1 |
| AKBA | 2021-08-25 | 2.1 | 2.7 | -1.6 | -1.2 |
| AKBA | 2021-08-24 | 2.1 | 2.6 | -1.5 | -1.1 |
AKBA Growth Metrics
- The year over year net cashflow from operations growth rate now stands at 56.22%.
- Its 5 year cash and equivalents growth rate is now at 165.6%.
- Its 2 year net income to common stockholders growth rate is now at -380.35%.
The table below shows AKBA's growth in key financial areas (numbers in millions of US dollars).
| Date | Revenue | Operating Cash Flow | Net Income to Common Stock |
|---|---|---|---|
| 2021-12-31 | 213.578 | -252.965 | -282.84 |
| 2021-09-30 | 210.672 | -220.939 | -299.162 |
| 2021-06-30 | 221.904 | -191.906 | -299.577 |
| 2021-03-31 | 259.133 | -91.545 | -392.29 |
| 2020-12-31 | 295.307 | -110.388 | -383.457 |
| 2020-09-30 | 308.163 | -171.741 | -390.94 |
AKBA's Quality Factors
The “Quality” component of the POWR Ratings focuses on 31 different factors of a companies fundamentals and operational strength. Here are some key insights as we drill into the specifics of these quality attributes.- AKBA has a Quality Grade of C, ranking ahead of 61.34% of graded US stocks.
- AKBA's asset turnover comes in at 0.347 -- ranking 132nd of 682 Pharmaceutical Products stocks.
- BPTH, ASLN, and ARDX are the stocks whose asset turnover ratios are most correlated with AKBA.
The table below shows AKBA's key quality metrics over time.
| Period | Asset Turnover | Gross Margin | ROIC |
|---|---|---|---|
| 2021-06-30 | 0.347 | 0.186 | -1.786 |
| 2021-03-31 | 0.385 | -0.169 | -2.192 |
| 2020-12-31 | 0.414 | -0.002 | -1.908 |
| 2020-09-30 | 0.414 | 0.121 | -1.912 |
| 2020-06-30 | 0.439 | 0.181 | -2.161 |
| 2020-03-31 | 0.442 | 0.596 | -1.469 |
AKBA Price Target
For more insight on analysts targets of AKBA, see our AKBA price target page. And for a list of of all stocks sorted by upside potential based on analyst target price, see our Top Price Target page.
| Average Price Target | $6.54 | Average Broker Recommendation | 1.62 (Moderate Buy) |
AKBA Stock Price Chart Interactive Chart >
AKBA Price/Volume Stats
| Current price | $0.42 | 52-week high | $3.35 |
| Prev. close | $0.41 | 52-week low | $0.30 |
| Day low | $0.40 | Volume | 1,723,593 |
| Day high | $0.42 | Avg. volume | 8,896,038 |
| 50-day MA | $0.40 | Dividend yield | N/A |
| 200-day MA | $1.45 | Market Cap | 77.03M |
Akebia Therapeutics, Inc. (AKBA) Company Bio
Akebia Therapeutics focuses on the development and commercialization of proprietary therapeutics based on hypoxia inducible factor (HIF) biology for patients with kidney disease. The company was founded in 2007 and is based in Cambridge, Massachusetts.
Latest AKBA News From Around the Web
Below are the latest news stories about Akebia Therapeutics Inc that investors may wish to consider to help them evaluate AKBA as an investment opportunity.
Akebia amends license agreement with Vifor for potential launch of kidney drugAkebia Therapeutics (AKBA -0.8%) amended a license agreement with Vifor Pharma < |
Akebia Therapeutics Announces Amendment of License Agreement with Vifor Pharma in Preparation for Potential Vadadustat LaunchAkebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, and Vifor Pharma Group (Vifor Pharma), today announced that the companies have amended and restated the terms of their license agreement, pursuant to which Akebia Therapeutics, Inc. (Akebia) granted Vifor Pharma an exclusive license to sell vadadustat, Akebia's investigational oral therapeutic for the treatment of anemia due to chronic kidney disease (C |
Akebia Therapeutics to Report Fourth Quarter and Full-Year 2021 Financial Results and Discuss Recent Business HighlightsAkebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, today announced plans to release its financial results for the fourth quarter and full-year 2021 ended December 31, 2021, on Tuesday, March 1, 2022. |
Akebia Therapeutics Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)Akebia Therapeutics, Inc. (Nasdaq: AKBA), a biopharmaceutical company with the purpose to better the lives of people impacted by kidney disease, granted 17 newly-hired employees options to purchase an aggregate of 129,000 shares of Akebia's common stock on January 31, 2022, as inducements material to each such employee's entering into employment with Akebia. The options were granted in accordance with Nasdaq Listing Rule 5635(c)(4). |
Top Biotech Stocks for Q1 2022The biotechnology industry includes companies that develop drugs and diagnostic technologies for the treatment of diseases and medical conditions. This means that investors may wait for years before knowing whether a drug under development will pay off. Many biotech companies have shifted their focus entirely or added COVID-19 vaccine and treatments to their product pipeline. |
AKBA Price Returns
| 1-mo | -0.45% |
| 3-mo | 25.60% |
| 6-mo | -76.67% |
| 1-year | -82.72% |
| 3-year | -91.06% |
| 5-year | -97.20% |
| YTD | -81.42% |
| 2021 | -19.29% |
| 2020 | -55.70% |
| 2019 | 14.29% |
| 2018 | -62.81% |
| 2017 | 42.84% |
Continue Researching AKBA
Here are a few links from around the web to help you further your research on Akebia Therapeutics Inc's stock as an investment opportunity:Akebia Therapeutics Inc (AKBA) Stock Price | Nasdaq
Akebia Therapeutics Inc (AKBA) Stock Quote, History and News - Yahoo Finance
Akebia Therapeutics Inc (AKBA) Stock Price and Basic Information | MarketWatch
Loading social stream, please wait...